AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024 Osaka, Japan & Lausanne, Switzerland & Cambridge, Mass., United States ACI-24.060 is an anti-Abeta active immunotherapy candidate...
